These results suggest that KRAS and BRAF mutations play a limited role in the development of ESCC and that mutation analysis is not useful as a screening test for sensitivity to anti-EGFR therapy in ESCC. This evidence concerns the gene BRAF and esophageal squamous cell carcinoma.